Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice
Miao, Congrong and Radu, Gertrud U. and Caidi, Hayat and Tripp, Ralph A. and Anderson, Larry J. and Haynes, Lia M.,, 90, 1119-1123 (2009),
doi = https://doi.org/10.1099/vir.0.009308-0,
publicationName = Microbiology Society,
issn = 0022-1317,
abstract= Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-γ) production in the lungs of RSV-infected mice. Its F(ab′)2 component only mediates decreased leukocyte trafficking and IFN-γ production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.,
language=,
type=